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Summary 
Background Closed-loop systems link continuous glucose measurements to insulin delivery. We aimed to establish 
whether closed-loop insulin delivery could control overnight blood glucose in young people. 
Methods We undertook three randomised crossover studies in 19 patients aged 5–18 years with type 1 diabetes of 
duration 6·4 years (SD 4·0). We compared standard continuous subcutaneous insulin infusion and closed-loop 
delivery (n=13; APCam01); closed-loop delivery after rapidly and slowly absorbed meals (n=7; APCam02); and closed-
loop delivery and standard treatment after exercise (n=10; APCam03). Allocation was by computer-generated random 
code. Participants were masked to plasma and sensor glucose. In APCam01, investigators were masked to plasma 
glucose. During closed-loop nights, glucose measurements were fed every 15 min into a control algorithm calculating 
rate of insulin infusion, and a nurse adjusted the insulin pump. During control nights, patients’ standard pump 
settings were applied. Primary outcomes were time for which plasma glucose concentration was 3·91–8·00 mmol/L 
or 3·90 mmol/L or lower. Analysis was per protocol. This trial is registered, number ISRCTN18155883. 
Findings 17 patients were studied for 33 closed-loop and 21 continuous infusion nights. Primary outcomes did not 
diﬀ er signiﬁ cantly between treatment groups in APCam01 (12 analysed; target range, median 52% [IQR 43–83] closed 
loop vs 39% [15–51] standard treatment, p=0·06; ≤3·90 mmol/L, 1% [0–7] vs 2% [0–41], p=0·13), APCam02 (six 
analysed; target range, rapidly 53% [48–57] vs slowly absorbed meal 55% [37–64], p=0·97; ≤3·90 mmol/L, 0% [0–4] vs 
0% [0–0], p=0·16]), and APCam03 (nine analysed; target range 78% [60–92] closed loop vs 43% [25–65] control, 
p=0·0245, not signiﬁ cant at corrected level; ≤3·90 mmol/L, 10% [2–15] vs 6% [0–44], p=0·27). A secondary analysis of 
pooled data documented increased time in the target range (60% [51–88] vs 40% [18–61]; p=0·0022) and reduced time 
for which glucose concentrations were 3·90 mmol/L or lower (2·1% (0·0–10·0) vs 4·1% (0·0–42·0); p=0·0304). No 
events with plasma glucose concentration lower than 3·0 mmol/L were recorded during closed-loop delivery, 
compared with nine events during standard treatment. 
Interpretation Closed-loop systems could reduce risk of nocturnal hypoglycaemia in children and adolescents with 
type 1 diabetes. 
Funding Juvenile Diabetes Research Foundation; European Foundation for Study of Diabetes; Medical Research 
Council Centre for Obesity and Related Metabolic Diseases; National Institute for Health Research Cambridge 
Biomedical Research Centre.
Introduction 
Type 1 diabetes is one of the most common chronic 
childhood diseases1 and incidence has doubled during 
the past 10 years.2 Children and adolescents need life-
long insulin treatment to achieve glucose control that is 
suﬃ  cient to prevent long-term complications.3 However, 
intensive insulin therapy is associated with increased 
risk of hypoglycaemia, which is the most feared 
complication for children and their parents, impeding 
eﬀ orts to achieve recommended glucose concentrations.4 
Technological developments in monitoring of glucose 
concentrations and methods for continuous insulin 
administration could reduce this risk. 
Continuous monitoring devices measure interstitial 
glucose as a marker of changes in blood glucose con-
centration.5 Although still less accurate than are blood 
glucose meters, devices have improved glucose control.6 
The established technique of continuous subcutaneous 
insulin infusion uses a portable electromechanical pump 
to mimic non-diabetic insulin delivery, infusing insulin 
at preselected rates—which are slow basal rates with 
patient-activated boosts at mealtimes.7 Continuous 
glucose monitoring devices and insulin pumps can be 
combined to form closed-loop systems. Insulin is then 
delivered according to real-time sensor glucose data, as 
directed by a control algorithm, rather than at pre-
programmed rates.
Few closed-loop prototypes have been developed8–10 
and progress has been hindered by suboptimum 
accuracy and reliability of monitoring devices, slow 
absorption of subcutaneously administered rapid-acting 
insulin analogues, and inadequate control algorithms.8 
Lancet 2010; 375: 743–51
Published Online
February 5, 2010
DOI: 10.1016/S0140-
6736(09)61998-X
See Comment page 702
Department of Paediatrics 
(R Hovorka PhD, J M Allen RN, 
D Elleri MD, L J Chassin PhD, 
T Hovorka MSc, A M F Larsen MSc, 
M Nodale MSc, A De Palma MD, 
M E Wilinska PhD, C L Acerini MD, 
Prof D B Dunger MD) and 
Institute of Metabolic Science 
(R Hovorka, J M Allen, D Elleri, 
L J Chassin, J Harris RN, 
A M F Larsen, M E Wilinska, 
C L Acerini, Prof D B Dunger), 
University of Cambridge, 
Cambridge, UK; and Jaeb Center 
for Health Research, Tampa, FL, 
USA (D Xing MPH, 
C Kollman PhD)
Correspondence to:
Dr Roman Hovorka, Institute of 
Metabolic Science, University of 
Cambridge, Box 289, 
Addenbrooke’s Hospital, Hills 
Road, Cambridge CB2 0QQ, UK
rh347@cam.ac.uk 
Articles
744 www.thelancet.com   Vol 375   February 27, 2010
We believe that these drawbacks can be overcome with 
commercially available continuous glucose monitoring 
and pump delivery systems in combination with 
advanced control algorithms, such as those that are 
based on model-predictive control.11 We aimed to 
establish whether closed-loop systems reduce risk of 
nocturnal hypoglycaemia and achieve good glucose 
control in children and adolescents, even after variable 
evening meal intake and diﬀ ering exercise patterns. 
Methods 
Patients and study design
From April, 2007, to September, 2008, children and 
adolescents were enrolled in three studies at the 
Wellcome Trust Clinical Research Facility, 
Addenbrooke’s Hospital (Cambridge, UK). Inclusion 
criteria were diagnosis of type 1 diabetes as deﬁ ned by 
WHO for at least 6 months or conﬁ rmed C-peptide 
negative, and treatment by continuous subcutaneous 
insulin infusion for at least 3 months. Exclusion criteria 
were recurrent severe hypoglycaemic unawareness or 
clinically signiﬁ cant nephropathy, neuropathy, or 
proliferative retinopathy. Participants and their 
caregivers were provided with age-appropriate patient 
information sheets. Participants aged 16 years and older 
and parents or guardians of patients aged younger than 
16 years signed the consent form. Study protocols were 
approved by the Cambridge Ethics Committee. Studies 
were done in accordance with the Declaration of 
Helsinki. 
Figure 1 shows the randomised crossover design of the 
three studies. We compared the closed-loop system with 
standard continuous subcutaneous insulin infusion 
(Artiﬁ cial Pancreas Project at Cambridge [APCam] 01), 
assessed eﬀ ects of a variable-content large evening meal 
(APCam02), and investigated eﬀ ects of moderate-
intensity evening exercise (APCam03).
Randomisation and masking 
The allocation sequence was generated by LJC and 
MEW with computer-generated random code and 
placed in sealed envelopes. Neither block nor strati-
ﬁ cation was used. Participants were masked to plasma 
and sensor glucose data. In APCam01, investigators 
were masked to plasma glucose data. No other masking 
was applied. 
Procedures
In APCam01, 13 patients aged 5–18 years were assigned 
to be treated with overnight closed-loop delivery or 
standard treatment on two occasions 1 to 3 weeks apart. 
2 weeks before the ﬁ rst study occasion, insulin pump 
delivery was optimised by analysing 72 h of non-real-time 
sensor glucose. On both occasions, patients consumed a 
self-selected meal (mean 87 g [SD 23] carbohydrates) at 
18.00 accompanied by prandial insulin (9 U [5]) calculated 
according to patients’ insulin-to-carbohydrate ratio and 
capillary ﬁ ngerstick glucose value. Meals were identical 
on both nights. Closed-loop control was applied between 
20.00 and 08.00. On continuous insulin infusion nights, 
patients’ standard insulin pump settings were applied. 
Between study nights, self-adjustment of insulin delivery 
was allowed. 
The ﬁ rst seven patients aged 12–18 years recruited for 
APCam01 were recruited for APCam02 and studied on 
two further occasions, 1 to 4 weeks apart. At 18.00 on 
both nights, patients consumed either a rapidly or 
slowly absorbed large meal selected from a list of 
standard meals diﬀ ering in glycaemic load (rapid, 
113 [29], vs slow, 40 [8]; p=0·001, paired t test) but 
matched for carbohydrates (129 g [34] vs 129 g [34]; p 
value not signiﬁ cant). The carbohydrate amount 
corresponded to largest meal eaten during the preceding 
3 months. Prandial insulin doses were similar (17 U [6] 
vs 17 U [7]) and were calculated according to patients’ 
insulin-to-carbohydrate ratio and sensor glucose 
concentrations. Closed-loop delivery was done from 
18.30 to 08.00. 
In APCam03, ten postpubertal patients aged 
12–18 years were assigned to be studied on two occasions. 
Six were new patients, not participating in APCam01 or 
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Figure 1: Trial design 
(A) APCam01 (12 nights per treatment). (B) APCam02 (six nights per treatment). (C) APCam03 (nine nights per 
treatment). APCam=Artiﬁ cial Pancreas Project at Cambridge. CSII=continuous subcutaneous insulin infusion. 
CRF=clinical research facility. Peak VO2=maximum oxygen uptake. Planned 1–3 weeks, but for logistical reasons 
extended to 24 and 27 days in two patients (*) and to 35 and 36 days in two patients (†).
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APCam02, and four were the ﬁ rst patients to be recruited 
for APCam01 who were postpubertal and willing to 
participate. A week before the ﬁ rst night, a ramped 
treadmill protocol was used to estimate maximum 
oxygen uptake (peak VO2).12 Subsequently, patients were 
studied after identical exercise protocols with closed-
loop delivery or continuous insulin infusion. At 16.00, 
patients ate a light meal chosen from a list of standard 
snacks (45 g [13] carbohydrates) accompanied by prandial 
bolus calculated from their insulin-to-carbohydrate ratio 
and sensor glucose concentrations. They exercised at 
55% of peak VO2 on a treadmill from 18.00 until 18.45 
with a 5-min rest at 18.20. Insulin was then delivered by 
closed loop between 20.00 and 08.00. On continuous 
insulin infusion nights, patients’ standard pump 
settings were applied. 
On every study occasion, on patients’ arrival at the 
clinical research facility a sampling cannula was inserted 
in an antecubital vein. Venous samples were obtained 
every 15 min for glucose estimation and every 30 min for 
insulin assay from 17.00 (or from 16.00 in APCam02) 
until 08.00. These data were not used to calculate or 
change insulin doses during continuous infusion or 
closed-loop delivery—doses were dependent on sensor 
glucose readings only. 
In APCam01, Guardian Real-Time (GRT; Medtronic 
MiniMed, Northridge, CA, USA) was used to measure 
real-time subcutaneous glucose during closed-loop 
control. During continuous insulin infusion, non-real-
time subcutaneous glucose was recorded by Continuous 
Glucose Monitoring System Gold (CGMS Gold; 
Medtronic MiniMed, Northridge, CA, USA). In 
APCam02 and APCam03, FreeStyle Navigator (Abbott 
Diabetes Care, Alameda, CA, USA) was used. Accuracy 
of the devices, measured as relative absolute diﬀ erence 
between sensor glucose and paired plasma glucose 
divided by plasma glucose, was 9·2% (4·3–16·7) for 
GRT and 7·6% (3·8–14·1) for CGMS. These two devices 
were calibrated at the clinical research facility every 6 h 
from 17.00 with venous glucose concentrations measured 
with Yellow Springs Instrument (YSI) analyser. The 
relative absolute diﬀ erence was 12·7% (5·6–21·9) for 
Navigator, as cali brated with capillary ﬁ ngersticks as per 
manufacturer’s instructions. Accuracy of GRT in our 
investigations was slightly better than reported data,13 
which is at least partly accounted for by highly accurate 
calibration of the device. Accuracy of Navigator was 
similar to reported data.13 
On arrival at the clinical research facility, patients’ 
insulin pumps were disconnected and the study pump 
Deltec Cozmo (Smiths Medical, St Paul, MN, USA) 
connected to the established subcutaneous infusion site 
delivering rapid-acting insulin analogue Aspart (Novo 
Nordisk, Bagsvaerd, Denmark). Plasma glucose was 
measured by YSI2300 STAT Plus Analyser (YSI, 
Farnborough, UK). Plasma insulin was measured with 
an immunochemiluminometric assay (Invitron, 
Monmouth, UK; intra-assay coeﬃ  cient of variation [CV] 
4·7%; interassay CV 7·2–8·1%). 
We used an adaptive algorithm for the closed-loop 
system that was based on model-predictive control.11 
Every 15 min, real-time sensor glucose was entered into 
the algorithm, which calculated infusion rates for the 
insulin pump which was manually adjusted by a nurse 
(ﬁ gure 2). The algorithm adopted a compartment model 
of glucose kinetics14 describing the eﬀ ect of rapid-acting 
insulin analogue and the carbohydrate content of meals 
on sensor glucose excursions. It was initialised with a 
patient’s weight, total daily insulin dose, and basal 
A
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Figure 2: Closed-loop algorithm 
Manual operation of the closed-loop system consists of three steps repeated every 15 min. Step 1: research nurse 
reads sensor glucose from continuous glucose monitoring (CGM) display (A) and types glucose concentration in a 
workﬂ ow wizard running on a laptop (B). Step 2: the wizard calls the control algorithm, which computes the 
insulin infusion rate that is subsequently displayed by the workﬂ ow wizard (C). Step 3: research nurse manually 
sets infusion rate on the insulin pump (A). Freestyle Navigator CGM device used in APCam02 and APCam03 and 
Deltec Cozmo insulin pump are shown (A). Data obtained during closed-loop are shown on the graphical user 
interface (D). Plot shows sensor glucose (red circle) and insulin infusion (blue line) obtained during a sample study 
in APCam03. Dashed red lines show target glucose range. Reproduced by permission of Smiths Medical ASD Inc 
(St Paul, MN, USA) and Abbott Diabetes Care (Alameda, CA, USA).
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insulin requirements. In real time, sensor glucose 
measurements were used to update two model 
variables—an endogenous glucose ﬂ ux correcting for 
errors in model-based predictions and carbohydrate 
bioavailability. Several competing models diﬀ ering in 
rate of subcutaneous insulin absorption and carbohydrate 
absorption proﬁ le were run in parallel.15 A combined 
model forecasted plasma glucose excursions during a 
2·5-h prediction horizon. Insulin infusion was calculated 
to achieve target glucose, which was set at 5·8 mmol/L, 
but was ﬂ exible and could increase up to 7·3 mmol/L if 
previous predictions were inaccurate. Safety rules could 
reduce insulin infusion to prevent overdosing. Algorithm 
version 0.00.02 to 0.01.05 was used. 
Primary outcomes were time for which plasma 
glucose concentration was in the target range 
(3·91–8·00 mmol/L) and lower than the target range 
(≤3·90 mmol/L) between 20.00 and 08.00 for APCam01 
and APCam03, and from 18.30 for APCam02. Secondary 
outcomes were mean glucose concentration, time for 
which glucose concentration was higher than 
8·0 mmol/L, mean rate of insulin infusion, and mean 
plasma insulin concentration. Low blood-glucose index 
assessed duration and extent of hypoglycaemia and 
was calculated as an average of transformed glucose 
measurements progressively increasing at low glucose 
concentrations.16 Grade A and B assessed eﬀ ectiveness 
and grade E and F assessed safety with glycaemic 
control grading,17 which deﬁ nes six glucose bands, 
A to F; band A implies excellent control and band F 
unsafe control. Secondary outcomes were calculated 
between start of closed-loop control and 08.00, and 
between midnight and 08.00. 
Statistical analysis 
APCam01 was an exploratory investigational study. 
Power calculations were not done for APCam02, because 
this was primarily a safety study and formally an 
extension of APCam01. In APCam03, closed-loop 
control was expected to reduce time spent at plasma 
glucose concentrations lower than 3·90 mmol/L by a 
mean of 38% (SD 35). Nine patients provided 80% 
power at 5% signiﬁ cance level to detect this diﬀ erence. 
For every outcome measure, a repeated measures 
regression model compared alternative treatments 
adjusting for a period eﬀ ect. Because many outcomes 
were not normally distributed, we calculated signiﬁ cance 
levels using a permutation test, which is a non-
parametric resampling procedure18 in which the null 
hypothesis of exchange ability is tested by comparison of 
the estimated treatment eﬀ ect from the regression 
Occasion 1
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Occasion 2
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7 randomly assigned
to closed-loop 
delivery
6 randomly assigned
to CSII
4 randomly assigned
to slow meal
3 randomly assigned
to rapid meal
6 randomly assigned
to closed-loop 
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4 randomly assigned
to CSII
1 dropout due to
cannulation 
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1 dropout due to
cannulation 
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participate
4 randomly assigned
to closed-loop 
delivery
5 randomly assigned
to CSII
3 randomly assigned
to slow meal
3 randomly assigned
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to closed-loop 
delivery
6 randomly assigned
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and analysed
6 completed study
and analysed
9 completed study
and analysed
Figure 3: Trial proﬁ le
APCam=Artiﬁ cial Pancreas Project at Cambridge. *All seven patients who entered APCam02 participated in APCam01. †Two who entered APCam03 participated in both APCam01 and 02; another 
two participated in APCam01 only.
APCam01 
(n=12)
APCam02 
(n=6)
APCam03 
(n=9)
APCam01–03 
(n=17)
Sex (male) 7 1 3 8
Age (years) 13·4 (4·3) 15·0 (2·2) 14·2 (2·1) 13·5 (3·6)
BMI (kg/m²) 21·9 (4·2) 22·9 (4·3) 19·8 (2·9) 21·0 (4·0)
HbA1c (%) 8·7% (2·0) 9·1% (2·4) 7·8% (1·0) 8·5% (1·8)
Duration of diabetes (years) 7·0 (4·5) 6·4 (4·4) 5·6 (3·2) 6·4 (4·0)
Duration on pump (years) 1·9 (1·1) 1·5 (0·9) 2·0 (1·2) 1·9 (1·1)
Total daily insulin (U/kg per day) 0·89 (0·27) 0·96 (0·16) 0·93 (0·23) 0·92 (0·24)
Data are mean (SD) or number. BMI=body-mass index. HbA1c=haemoglobin A1c. APCam=Artiﬁ cial Pancreas Project at 
Cambridge. 
Table 1: Patient characteristics
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model with those from a generated sample in which 
patients are rerandomised according to order of closed-
loop versus control nights. 
During trial planning, all three studies were outlined 
together, justifying, although not stated in study 
protocols, a secondary pooled analysis of APCam01 and 
APCam03. The permutation test took into account that 
four patients participated in both APCam01 and 
APCam03. Analyses were done with SAS software 
(version 9.1) and SPSS (version 15). The Bonferroni 
method was used for the four primary comparisons, 
setting the threshold for signiﬁ cance to 1·25% (5%÷4). 
No formal adjustment was made for other analyses, 
which were regarded as secondary and hypothesis-
generating. 
This trial is registered, number ISRCTN18155883. 
Role of the funding source 
Juvenile Diabetes Research Foundation and Abbott 
Diabetes Care read the report before submission. No 
sponsor had any role in the study design, data collection, 
data analysis, data interpretation, or writing of the report. 
APCam01 APCam03
CL (n=12) CSII (n=12) p value CL (n=9) CSII (n=9) p value*
From start of closed-loop†
Plasma glucose at start (mmol/L) 10·2 (3·6) 11·4 (5·3) 0·66 6·8 (2·2) 11·7 (5·9) 0·0290
Overnight glucose (mmol/L) 7·8 (1·7) 8·3 (3·4) 0·75 5·9 (1·3) 7·8 (4·1) 0·28
SD of overnight glucose (mmol/L) 2·2 (1·6–3·0) 2·1 (1·5–2·7) 0·87 0·9 (0·8–1·5) 2·4 (1·8–3·6) 0·06
Time for which plasma glucose ≤3·5 mmol/L (%) 0·0% (0·0–0·0) 0·0% (0·0–21·0) 0·13 4·1% (0·0–6·1) 0·0% (0·0–28·0) 0·19
Time for which plasma glucose >8·0 mmol/L (%) 43% (12–57) 36% (19–74) 0·59 0% (0–25) 31% (10–54) 0·09
LBGI 0·4 (0·0–2·3) 1·1 (0·1–6·3) 0·14 2·8 (0·9–3·1) 3·6 (0·6–7·4) 0·20
Grade A and B (%) 36% (22–65) 26% (10–41) 0·18 60% (51–83) 16% (10–32) 0·0104
Grade E and F (%) 0·0% (0·0–6·1) 8·0% (0·0–35·1) 0·10 0·0% (0·0–1·4) 13·7% (6·4–41·9) 0·0188
Insulin infusion (U/h) 1·2 (0·6–2·0) 1·1 (0·6–1·8) 0·40 0·8 (0·6–1·0) 0·9 (0·7–1·2) 0·42
Plasma insulin concentration (pmol/L) 207 (149–368) 238 (148–349) 0·80 199 (148–453) 229 (146–469) 0·23
After midnight‡
Time for which plasma glucose in target range (%) 76% (61–89) 35% (1·5–71·0) 0·0351 91% (76–100) 35% (13–64) 0·0268
Time for which plasma glucose ≤3·90 mmol/L (%) 1·5% (0·0–11·0) 3·0% (0·0–61·0) 0·13 3·0% (0·0–15·0) 9·1% (0·0–42·0) 0·22
Overnight glucose (mmol/L) 6·8 (1·6) 7·3 (3·8) 0·68 5·7 (1·3) 6·6 (4·1) 0·68
SD of overnight glucose (mmol/L) 1·2 (1·1–1·9) 1·1 (0·6–1·4) 0·52 0·7 (0·5–0·9) 0·8 (0·4–2·4) 0·47
Time for which plasma glucose ≤3·5 mmol/L (%) 0·0% (0·0–0·0) 0·0% (0·0–30·0) 0·12 0·0% (0·0–6·1) 0·0% (0·0–24·0) 0·26
Time for which plasma glucose >8·0 mmol/L (%) 20% (0–39) 9·1% (0–83) 0·42 0·0% (0·0–0·0) 0·0% (0·0–62·0) 0·32
LBGI 0·6 (0·1–2·8) 1·6 (0–9·2) 0·13 2·0 (0·6–3·5) 4·6 (0·9–9·1) 0·21
Grade A and B (%) 45% (32–65) 18% (0–58) 0·15 72% (60–100) 9% (2–18) 0·0173
Grade E and F (%) 0·0% (0·0–0·0) 11·9% (0·0–27·2) 0·0100 0·0% (0·0–1·5) 17·7% (9·5–20·5) 0·0493
Insulin infusion (U/h) 1·2 (0·6–1·6) 1·1 (0·5–1·7) 0·89 0·8 (0·5–1·0) 0·8 (0·8–1·0) 0·20
Plasma insulin concentration (pmol/L) 154 (121–314) 197 (121–300) 0·79 195 (143–434) 232 (142–433) 0·25
Data are mean (SD) or median (IQR). Plasma glucose target range was 3·91–8·00 mmol/L. For details of grading system see reference 17. APCam=Artiﬁ cial Pancreas Project at 
Cambridge. CL=closed-loop delivery. CSII=continuous subcutaneous insulin infusion. LBGI= low blood-glucose index. *No formal adjustment done for multiple comparisons 
for secondary comparisons; results should therefore be regarded as hypothesis generating rather than conclusive. †From start of closed-loop control at 20.00 to 08.00. 
‡From midnight to 08.00.
Table 3: Secondary comparisons in APCam01 and APCam03 
APCam01 (n=12*) APCam03 (n=9*) APCam01 and 03 combined (n=21†)
CL CSII p value CL CSII p value CL CSII p value
Time when plasma glucose in 
target range (%)
52% (43–83) 39% (15–51) 0·06‡ 78% (60–92) 43% (25–65) 0·0245‡ 60% (51–88) 40% (18–61) 0·0022§
Time when plasma glucose 
≤3·90 mmol/L (%)
1·0% (0·0–7·1) 2·0% (0·0–41·0) 0·13‡ 10·0% (2·0–15·0) 6·1% (0·0–44·0) 0·27‡ 2·1% (0·0–10·0) 4·1% (0·0–42·0) 0·0304§
Data are median (interquartile range). Plasma glucose target range was 3·91–8·00 mmol/L. Data for APCam01 and 03 presented separately are from primary analysis; pooled data are results of secondary analysis. 
CL=closed-loop delivery. CSII=continuous subcutaneous insulin infusion. APCam=Artiﬁ cial Pancreas Project at Cambridge. *Number of patients. †Number of nights per treatment. ‡Bonferroni correction used—
ie, p value of less than 0·0125 (0·05÷4)  regarded as signiﬁ cant. §No formal adjustment for multiple comparisons was done for secondary comparisons.
Table 2: Outcomes of APCam01 and APCam03
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The corresponding author had full access to all data in 
the study and had ﬁ nal responsibility for the decision to 
submit for publication. 
Results 
From April, 2007, to September, 2008, 19 children and 
adolescents were enrolled in three studies (ﬁ gure 3). Two 
patients participated in three study protocols, six in two, 
and nine in one. After the ﬁ rst study night, two patients 
dropped out (ﬁ gure 3). Table 1 summarises patient 
characteristics. Data from participants in APCam01 
showed that time in the target range for plasma glucose 
was higher during closed-loop delivery than during 
standard delivery, but the increase was not signiﬁ cant 
(table 2). Time lower than the target range was not 
signiﬁ cantly reduced (table 2). Table 3 shows secondary 
outcomes for APCam01 and APCam03. Total overnight 
insulin dose did not diﬀ er between treatments. Sensor-
based assessments and time concentration proﬁ les are 
shown in the webappendix (pp 2, 4, 6–8). During closed-
loop delivery, variability in plasma glucose decreased 
from midnight (webappendix pp 6, 8). 
Overnight glucose control in APCam02 did not diﬀ er 
after consumption of the two meals (table 4). Time in 
target range was similar to data recorded in APCam01 
during closed-loop delivery. Incremental glucose area-
under-the-curve between 18.00 and 22.00 was highest 
after the rapidly absorbed meal, but this ﬁ nding was not 
signiﬁ cant (mean 1021 mmol/L [SD 807] vs -234 mmol/L 
[481] per 240 min; p=0·08). 
Closed-loop delivery after early evening exercise in 
APCam03 provided the greatest amount of the time spent 
in the target range of the three studies, but the 
improvement compared with data for standard treatment 
was not signiﬁ cant at the corrected level. During 
continuous infusion one patient presented with plasma 
glucose lower than 2·0 mmol/L and was given oral 
glucose (GlucoGel, BBI Healthcare, UK), resulting in 
study termination for that patient. 
Table 5 summarises hypoglycaemic and hyper glycaemic 
events. All hypoglycaemic events were asymptomatic. 
During closed-loop delivery, the lowest plasma glucose 
concentration (3·0 mmol/L) was reported during 
APCam03 from 02.00 to 02.45, whereas sensor glucose 
was 4·2 mmol/L or higher. From 21.45 to 22.45, and from 
00.15 to 01.30, another patient participating in APCam03 
presented with plasma glucose concentrations between 
3·1 and 3·3 mmol/L with a value of 3·0 mmol/L at 00.45. 
Sensor glucose was 4·1 mmol/L or higher. Combining 
data obtained during all closed-loop studies, 11 (<1%) of 
1660 plasma glucose measurements were lower than 
3·3 mmol/L, and 24 (>1%) were lower than 3·5 mmol/L. 
No measurements lower than 3·0 mmol/L were recorded. 
Combining data obtained during continuous insulin 
infusion, eight of 992 (<1%) plasma glucose values 
were lower than 2·5 mmol/L, 32 (3%) were lower than 
3·0 mmol/L, 74 (7%) were lower than 3·3 mmol/L, and 
108 (11%) were lower than 3·5 mmol/L. 
Results of secondary analysis of pooled APCam01 and 
APCam03 data suggested that closed-loop delivery 
increased time for which plasma glucose was in the 
APCam01 (n=12) APCam02 (n=6) APCam03 (n=9) All studies
CL CSII CL-RA* CL-SA* CL† CSII CL CSII
Plasma glucose ≤2·0 mmol/L
Any ·· ·· ·· ·· ·· 1 ·· 1
<30 min ·· ·· ·· ·· ·· 1‡ ·· 1‡
Plasma glucose 2·1–2·5 mmol/L 
Any ·· 1 ·· ·· ·· 1 ·· 2
<30 min ·· ·· ·· ·· ·· ·· ·· ··
30–60 min ·· 1 ·· ·· ·· ·· ·· 1
60–90 min ·· ·· ·· ·· ·· 1 ·· 1
Plasma glucose >2·5 to 3·0 mmol/L
Any ·· 3 ·· ·· 1§ 3 1§ 6
<30 min ·· 1 ·· ·· ·· 1 ·· 2
30–60 min ·· 1 ·· ·· 1§ 2 1§ 3
60–240 min ·· ·· ·· ·· ·· ·· ·· ··
240–360 min ·· 1 ·· ·· ·· ·· ·· 1
(Continues on next page)
Rapidly absorbed 
evening meal (n=6)
Slowly absorbed 
evening meal (n=6)
p value*
From start of closed-loop†
Plasma glucose at start (mmol/L) 11·3 (6·5) 13·1 (5·8) 0·67
Time for which plasma glucose in target range (%) 53% (48–57) 55% (37–64) 0·97
Time for which plasma glucose ≤3·90 mmol/L (%) 0·0% (0·0–3·6) 0·0% (0·0–0·0) 0·16
Overnight glucose (mmol/L) 9·3 (3·1) 8·9 (2·2) 0·83
SD of overnight glucose (mmol/L) 3·0 (1·7–4·5) 2·4 (1·8–3·8) 0·68
Time for which plasma glucose ≤3·5 mmol/L (%) 0·0% (0·0–0·0) 0·0% (0·0–0·0) 0·50
Time for which plasma glucose >8·0 mmol/L (%) 46% (38–52) 45% (36–63) 0·95
LBGI 0·3 (0·0–1·4) 0·2 (0·1–0·3) 0·26
Grade A and B (%) 42% (29–46) 45% (32–77) 0·69
Grade E and F (%) 2·3% (0·0–15·4) 2·2% (0·0–8·9) 0·87
Insulin infusion (U/h) 1·7 (1·2–1·8) 1·4 (0·8–1·9) 0·46
Plasma insulin concentration (pmol/L) 250 (157–415) 222 (185–540) 0·60
After midnight‡
Time for which plasma glucose in target range (%) 86% (47–91) 83% (33–100) 0·98
Time for which plasma glucose ≤3·90 mmol/L (%) 0·0% (0·0–0·0) 0·0% (0·0–0·0) 0·50
Overnight glucose (mmol/L) 7·4 (1·7) 7·4 (1·9) >0·99
SD of overnight glucose (mmol/L) 1·4 (1·1–1·8) 1·4 (0·9–2·1) 0·92
Time for which plasma glucose ≤3·5 mmol/L (%) 0·0% (0·0–0·0) 0·0% (0·0–0·0) 0·50
Time for which plasma glucose >8·0 mmol/L (%) 14% (6·1–53·0) 17% (0–67) 0·97
LBGI 0·4 (0·0–1·0) 0·4 (0·2–0·6) 0·50
Grade A and B (%) 55% (35–68) 72% (23–88) 0·71
Grade E and F (%) 0·0% (0·0–2·4) 0·0% (0·0–6·6) >0·99
Insulin infusion (U/h) 1·1 (0·9–1·7) 1·2 (0·8–1·3) 0·77
Plasma insulin concentration (pmol/L) 129 (111–250) 117 (101–415) 0·44
Data are mean (SD) or median (IQR). Plasma glucose target range was 3·91–8·00 mmol/L. For details of grading system 
see reference 17. LBGI=low blood-glucose index. APCam=Artiﬁ cial Pancreas Project at Cambridge. *No formal 
adjustment for multiple comparisons was done for secondary comparisons. †From the start of closed-loop control at 
18.30 to 08.00. ‡From midnight to 08.00. 
Table 4: Comparisons in APCam02 
Articles
www.thelancet.com   Vol 375   February 27, 2010 749
target range and reduced time lower than the target range 
(table 2). A more apparent improvement in time within 
target was recorded after midnight, when closed-loop 
delivery became fully eﬀ ective (table 6). At low and high 
glucose concentrations, closed-loop control consistently 
outperformed continuous infusion (ﬁ gure 4). Pooled data 
from all closed-loop studies showed that plasma glucose 
was lower than the target range for 4% of the time, within 
target for 61%, and higher for 35%. Time in target 
increased to 75% for data obtained after midnight, which 
was when closed-loop control became fully eﬀ ective.
Discussion 
Our results show that overnight manual closed-loop 
insulin delivery can improve glucose control and reduce 
risk of hypoglycaemia in young patients with type 1 
diabetes. Secondary analysis of pooled data showed that 
time for which plasma glucose concentration was in the 
target range increased and frequency of low plasma 
glucose concentrations was reduced during closed-loop 
control. For data obtained after midnight, time spent in 
the target range more than doubled during closed loop 
compared with continuous infusion. Average overnight 
insulin delivery was similar during closed-loop delivery 
and standard treatment. 
Closed-loop systems could transform management of 
type 1 diabetes, but their introduction is likely to be 
gradual, starting from straightforward applications such 
as shutting oﬀ  of the pump at low glucose concentrations19 
or overnight closed-loop delivery, proceeding to more 
complex applications providing 24-h control. Overnight 
closed-loop delivery is appealing because it addresses the 
issue of nocturnal hypoglycaemia. On standard insulin 
regimens, 45–60% of young people can have profound, 
severe, persistent, and generally asymptomatic hypo-
glycaemia overnight.20 Ability to recognise hypo glycaemia 
is diﬃ  cult for children with type 1 diabetes and their 
parents. For children, poor ability to detect low blood 
glucose concentrations could be a substantial and 
underappreciated risk factor for severe hypoglycaemia.21 
Prevention of hypoglycaemia overnight could also 
improve daytime glucose control. 
Transiently high or persistently raised postprandial 
glucose concentrations can lead to insulin stacking and 
overdosing, resulting in late postprandial hyper-
insulinaemia and subsequent hypoglycaemia, as reported 
with some closed-loop algorithms.22 In our studies, 
postprandial glucose concentrations were increased after 
large evening meals, but overall glucose control was 
unaﬀ ected and risk of hypoglycaemia was low, 
documenting eﬀ ective, non-aggressive insulin delivery. 
Moderate-intensity late-afternoon or early-evening 
exercise in young people is a frequent occurrence and 
increases glucose requirements in the early morning, 
exacerbating risk of nocturnal hypoglycaemia.23 Our 
closed-loop algorithm ameliorated this risk and 
maintained good glucose control. 
CL (n=21) CSII (n=21) p value*
From start of closed-loop†
Overnight glucose (mmol/L) 7·0 (1·8) 8·1 (3·6) 0·29
SD of overnight glucose (mmol/L) 1·6 (1·1–2·8) 2·4 (1·7–3·2) 0·19
Time for which plasma glucose ≤3·5 mmol/L (%) 0·0% (0·0–4·1) 0·0% (0·0–23) 0·0237
Time for which plasma glucose >8·0 mmol/L (%) 25% (0·0–45·0) 35% (18–61) 0·13
LBGI 1·1 (0·1–2·7) 1·6 (0·1–6·6) 0·0330
Grade A and B (%) 51% (34–74) 26% (10–38) 0·0061
Grade E and F (%) 0·0% (0·0–5·2) 11·8% (0·1–40·9) 0·0049
Insulin infusion (U/h) 1·0 (0·6–1·4) 0·9 (0·6–1·6) 0·58
Plasma insulin concentration (pmol/L) 199 (148–405) 233 (146–383) 0·23
After midnight‡
Time for which plasma glucose in target range (%) 79% (64–97) 35% (3·0–64) 0·0025
Time for which plasma glucose ≤3·90 mmol/L (%) 3·0% (0·0–12·0) 6·1% (0·0–61·0) 0·0277
Overnight glucose (mmol/L) 6·3 (1·6) 7·0 (3·8) 0·51
SD of overnight glucose (mmol/L) 1·1 (0·7–1·6) 1·1 (0·5–1·6) 0·83
Time for which plasma glucose ≤3·5 mmol/L (%) 0·0% (0·0–0·0) 0·0% (0·0–27·0) 0·0292
Time for which plasma glucose >8·0 mmol/L (%) 0·0% (0·0–24·0) 3·0% (0·0–66·0) 0·18
LBGI 1·0 (0·1–3·1) 2·4 (0·1–9·1) 0·0347
Grade A and B (%) 60% (39–78) 10% (0–46) 0·0067
Grade E and F (%) 0·0% (0·0–0·0) 16·8% (0·0–23·9) 0·0008
Insulin infusion (U/h) 0·9 (0·6–1·4) 0·9 (0·6–1·6) 0·52
Plasma insulin concentration (pmol/L) 173 (125–363) 200 (142–337) 0·23
Data are mean (SD) or median (IQR). Plasma glucose target range was 3·91–8·00 mmol/L.  Time in target and time 
below target from start of closed-loop delivery are shown in table 2. For details of grading system see reference 17. 
CL=closed-loop delivery. n=number of nights per treatment. CSII=continuous subcutaneous insulin infusion. LBGI=low 
blood-glucose index. APCam=Artiﬁ cial Pancreas Project at Cambridge. *No formal adjustment for multiple 
comparisons was done for secondary comparisons; results should therefore be regarded as hypothesis-generating 
rather than conclusive. †From  start of closed-loop control at 20.00 to 08.00. ‡From midnight to 08.00. §APCam02 
did not provide CSII data.
Table 6: Comparisons between closed-loop delivery and continuous subcutaneous insulin infusion after 
pooling APCam01 and APCam03 data§ 
APCam01 (n=12) APCam02 (n=6) APCam03 (n=9) All studies
CL CSII CL-RA* CL-SA* CL† CSII CL CSII
(Continued from previous page)
Plasma glucose ≥16·7 mmol/L
Any 1 (1) 1 (1) 2 (1) 2 (2) ·· 3 (2) 5 (4) 4 (3)
<30 min ·· ·· ·· ·· ·· 1 (0) ·· 1
30–60 min 1 (1) ·· ·· ·· ·· ·· 1 (1) ··
60–120 min ·· ·· 1 (0) 1 (1) ·· ·· 2 (1) ··
120–180 min ·· ·· ·· 1 (1) ·· 1 (1) 1 (1) 1 (1)
180–240 min ·· ·· ·· ·· ·· ·· ·· ··
240–360 min ·· 1 (1) 1 (1) ·· ·· 1 (1) 1 (1) 2 (2)
Data in parentheses are number of occasions for which study started with plasma glucose 16·7 mmol/L or higher. After 
start of study (20.00 for APCam01 and APCam03, 18.30 for APCam03), all hypoglycaemic events were asymptomatic 
and, apart from for one patient‡, no treatment was given. All hypoglycaemic events at 3·0 mmol/L or less occurred at 
or after midnight. APCam=Artiﬁ cial Pancreas Project at Cambridge. CL=closed-loop delivery. CSII=continuous 
subcutaneous insulin infusion. *Closed-loop delivery after rapidly (RA) or slowly (SA) absorbed evening meal. 
†During closed-loop delivery in APCam03, two patients presented with hypoglycaemia during exercise with plasma 
glucose concentration lower than 3 mmol/L and were given 15 g carbohydrate. ‡Study stopped at 04.00 when plasma 
glucose was lower than 2·0 mmol/L and oral glucose was consumed; duration of hypoglycaemia could not be 
established. §Three consecutive plasma glucose values at 3·0 mmol/L.
Table 5: Frequency and duration of hypoglycaemia and hyperglycaemia during closed-loop delivery and 
continuous subcutaneous insulin infusion
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Apart from during continuous infusion in one patient, 
we did not give supplemental carbohydrates or insulin. 
Real-time alarms or predictive alarms could be used to 
avoid or reverse low glucose concentrations.24 To detect 
the two most pronounced hypoglycaemia events reported 
during our closed-loop studies, a high sensor alarm 
threshold of 4·2 mmol/L would be needed. Patients 
sleep through 70% of individual alarms and 35% of 
repeated alarm events,25 possibly because of alarm 
fatigue induced by a high frequency of false-positive 
alarms. Alarm-based hypoglycaemia detection and 
prevention is therefore of limited reliability, but could 
further reduce hypoglycaemia risk during overnight 
closed-loop delivery. 
Using Medtronic’s closed-loop system of external 
physiological insulin delivery,22 Weinzimer and 
colleagues26 assessed a proportional-integral-derivative 
control algorithm and Guardian Real-Time in 
17 adolescents and showed excellent control and 
feasibility of a hybrid closed-loop system during day and 
night. Three hypoglycaemic events at venous glucose 
concentrations of 3·3 mmol/L or lower were recorded 
and treated, all between 23.00 and 01.00. Schaller and co-
workers27 investigated closed-loop delivery during fasting 
conditions in adults. However, no studies have compared 
closed-loop delivery and continuous subcutaneous 
insulin infusion, or assessed the eﬀ ect of large evening 
meals or exercise. 
Insulin requirements vary greatly between individuals, 
and to a lesser degree diurnally and from day to day.28 
Our control algorithm coped with these variations 
eﬀ ectively by initialising individual insulin sensitivity 
from patients’ total daily insulin dose and usual basal 
insulin requirements and then adapting this estimate in 
real time on the basis of administered insulin and 
resulting sensor glucose concentrations. The adaptive 
nature of the control algorithm resulted in safe and 
eﬀ ective insulin dosing. 
Sensing errors have been perceived as the main obstacle 
to safe and eﬃ  cacious closed-loop glucose control.29,30 In 
our studies, the sensors did well, although we registered 
temporal losses of accuracy that were attributable to 
sensor artifacts and persistent deviations caused by 
calibration errors. During closed-loop delivery, sensing 
errors reduced time in target by 10–15%, but average 
plasma and sensor glucose concentrations were almost 
identical. Advancements in glucose-sensing technologies 
could further improve performance of closed-loop 
systems. Fully automated closed-loop delivery will need 
wireless data transmission to replace manual control of 
the pump by nurses. These technological steps are 
important but routine and should not aﬀ ect closed-loop 
performance. 
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